Identifying clinically important indicators for providing high quality breast cancer care.
Abstract
565 Background: Delivery of high-quality breast cancer care is a universal mandate in many global healthcare systems. The WHO Global Breast Cancer Initiative (GBCI) highlights timeliness of diagnosis and treatment initiation as a major component of improving patient outcomes and decreasing global disparity for breast cancer care. However, it is unclear whether the scientific evidence and clinician perspectives regarding high-quality breast cancer care practices are aligned. The aim of this study was to identify clinically important indicators associated with high-quality breast cancer care and assess whether indicators identified by breast cancer clinicians in British Columbia, Canada, are represented in the published literature and epidemiological data. Alignment is important to ensure benchmarking and quality improvement reflect both evidence and clinical priorities. Methods: A modified Delphi survey of breast cancer clinicians across BC was completed; consensus was pre-specified as >=85% agreement. A systematic literature review was conducted by BC Cancer Library Services to identify published breast cancer quality indicators and benchmarks associated with clinical outcomes. Clinician-identified indicators were then cross-referenced with the systematic literature review to identify evidence-based benchmarks associated with improved outcomes for the delivery of high-quality breast cancer care. Concordance between clinician priorities and reported quality measures was assessed. Results: 178 clinicians were invited to complete the survey, with a response rate of 42%. Of the 50 indicators initially identified, 18 reached consensus. Among the 18, the two highest ranked indicators that reached 100% consensus were “time from identification of symptom/screening abnormality to diagnosis,” and “time between diagnosis and starting treatment” which were consistent with the WHO GBCI. The systematic literature review identified 107 papers addressing quality indicators for breast cancer care. The two indicators were identified in 13% and 11% of studies, respectively. Although benchmark time cutoffs were reported in some studies, there was substantial variability and no benchmark threshold was consistently associated with improved outcomes. Conclusions: Clinicians strongly prioritize timeliness of diagnosis and initiation of treatment as indicators of high-quality breast cancer care, consistent with the WHO GBCI. However, these indicators were infrequently represented in the literature and lack consistently validated benchmarks. Future population-based studies and real-world evidence should investigate the relationship between diagnostic and treatment intervals and patient outcomes to establish evidence-based benchmarks for quality measurements and improvements.